Catalent, Pfizer in Supply Pact for Nexium OTC
By

Catalent Pharma Solutions has entered into an exclusive long term supply agreement to produce Pfizer Inc.'s over-the-counter (OTC) heartburn treatment, Nexium 24HR (esomeprazole), also marketed as Nexium Control outside the United States.

Under the agreement, Catalent's Winchester, Kentucky, facility will formulate and manufacture the 20 mg proton pump inhibitor drug into enteric coated, delayed-release pellets using fluid bed technology. Catalent will also encapsulate these pellets into two-piece, hard-shell capsules, where the company has invested in capsule banding technology required for OTC products.

Pfizer secured the exclusive global rights to market Nexium for the approved OTC indications from AstraZeneca in 2012. AstraZeneca continues to manufacture and sell the prescription product.

Source: Catalent

Leave a Reply

Your email address will not be published. Required fields are marked *